Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MAIA Biotechnology, Inc.MAIA · Entity 6919 | Director | September 30, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MAIA Biotechnology, Inc.
Report date September 30, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $1.18 · Expires 2036-09-30 | Direct | 32,012 |
Reported balance
After 2026-09-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-30 · Grant · Acquired 32,012 · Balance 32,012 F1: The stock options, granted on September 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options, granted on September 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 30, 2026 Filed Oct 3, 2026 00:20 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | GrantStock Options · Derivative | 32,012 | $0.00 Strike: $1.18 | $0.00 |
DisclosureSEC source: 0001878313-26-000100 · form4.xml · derivative · entry 1 Theagene Jean-Manasse · CIK 0001969857 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,012 Underlying: Common Stock · 32,012 shares Expires 2036-09-30 F1 · derivative.exercise_date: The stock options, granted on September 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 20:09 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | GrantStock Options · Derivative | 26,355 | $0.00 Strike: $1.44 | $0.00 |
DisclosureSEC source: 0001878313-26-000069 · form4.xml · derivative · entry 1 Theagene Jean-Manasse · CIK 0001969857 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,355 Underlying: Common Stock · 26,355 shares Expires 2036-06-30 F1 · derivative.exercise_date: The stock options, granted on June 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:50 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | GrantStock Options · Derivative | 27,258 | $0.00 Strike: $1.40 | $0.00 |
DisclosureSEC source: 0001878313-26-000031 · form4.xml · derivative · entry 1 Theagene Jean-Manasse · CIK 0001969857 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,258 Underlying: Common Stock · 27,258 shares Expires 2036-03-31 F1 · derivative.exercise_date: The stock options, granted on March 31, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 13:44 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | GrantOptions · Derivative | 24,060 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001878313-26-000018 · form4.xml · derivative · entry 1 Theagene Jean-Manasse · CIK 0001969857 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,060 Underlying: Common Stock · 24,060 shares Expires 2035-12-31 F1 · derivative.exercise_date: The stock options, granted on December 31, 2025 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date. Read SEC document |
| October 02, 2025 Filed Oct 6, 2025 20:29 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | GrantStock Options · Derivative | 20,459 | $0.00 Strike: $1.80 | $0.00 |
DisclosureSEC source: 0001878313-25-000035 · form4.xml · derivative · entry 1 Theagene Jean-Manasse · CIK 0001969857 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,459 Underlying: Common Stock · 20,459 shares Expires 2035-10-02 F1 · derivative.exercise_date: The stock options, granted on October 2, 2025, pursuant to the MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date. Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 20:13 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | GrantStock Options · Derivative | 20,380 | $0.00 Strike: $1.80 | $0.00 |
DisclosureSEC source: 0001127602-25-018648 · form4.xml · derivative · entry 1 Theagene Jean-Manasse · CIK 0001969857 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,380 Underlying: Common Stock · 20,380 shares Expires 2035-06-30 F1 · derivative.exercise_date: The stock options, granted on June 30, 2025 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date. Read SEC document |
| April 04, 2025 Filed Apr 8, 2025 20:41 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | GrantStock Options · Derivative | 20,291 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001127602-25-011809 · form4.xml · derivative · entry 1 Theagene Jean-Manasse · CIK 0001969857 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,291 Underlying: Common Stock · 20,291 shares Expires 2035-04-04 F1 · derivative.exercise_date: The stock options, granted on April 4, 2025 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 21:05 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | GrantStock Options · Derivative | 10,225 | $0.00 Strike: $1.98 | $0.00 |
DisclosureSEC source: 0001127602-25-000375 · form4.xml · derivative · entry 1 Theagene Jean-Manasse · CIK 0001969857 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,225 Underlying: Common Stock · 10,225 shares Expires 2034-12-31 F1 · derivative.exercise_date: The stock options, granted on December 31, 2024 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date. Read SEC document |
| September 30, 2024 Filed Oct 2, 2024 20:45 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | GrantStock Options · Derivative | 7,232 | $0.00 Strike: $2.81 | $0.00 |
DisclosureSEC source: 0001127602-24-024933 · form4.xml · derivative · entry 1 Theagene Jean-Manasse · CIK 0001969857 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,232 Underlying: Common Stock · 7,232 shares Expires 2034-09-30 F1 · derivative.exercise_date: The stock options, granted on September 30, 2024 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of thate date. Read SEC document |
| June 30, 2024 Filed Jul 2, 2024 20:08 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | GrantStock Options · Derivative | 5,728 | $0.00 Strike: $3.42 | $0.00 |
DisclosureSEC source: 0001127602-24-019835 · form4.xml · derivative · entry 1 Theagene Jean-Manasse · CIK 0001969857 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,728 Underlying: Common Stock · 5,728 shares Expires 2034-06-30 F1 · derivative.exercise_date: The stock options, granted on June 30, 2024 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date. Read SEC document |
| March 31, 2024 Filed Apr 2, 2024 20:52 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | GrantStock Options · Derivative | 9,193 | $0.00 Strike: $2.20 | $0.00 |
DisclosureSEC source: 0001127602-24-011875 · form4.xml · derivative · entry 1 Theagene Jean-Manasse · CIK 0001969857 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,193 Underlying: Common Stock · 9,193 shares Expires 2034-03-31 F1 · derivative.exercise_date: The stock options, granted on March 31, 2024 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date. Read SEC document |
| December 31, 2023 Filed Jan 4, 2024 01:57 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | GrantStock Options · Derivative | 15,418 | $0.00 Strike: $1.17 | $0.00 |
DisclosureSEC source: 0001127602-24-000643 · form4.xml · derivative · entry 1 Theagene Jean-Manasse · CIK 0001969857 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,418 Underlying: Common Stock · 15,418 shares Expires 2033-12-31 F1 · derivative.exercise_date: The stock options, granted on December 31, 2023 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date. Read SEC document |
| September 30, 2023 Filed Oct 3, 2023 20:14 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | GrantStock Options · Derivative | 8,378 | $0.00 Strike: $2.20 | $0.00 |
DisclosureSEC source: 0001127602-23-025164 · form4.xml · derivative · entry 1 Theagene Jean-Manasse · CIK 0001969857 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,378 Underlying: Common Stock · 8,378 shares Expires 2033-09-30 F1 · derivative.exercise_date: The stock options, granted on September 30, 2023 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 12:13 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | GrantStock Options · Derivative | 8,910 | $0.00 Strike: $2.20 | $0.00 |
DisclosureSEC source: 0001127602-23-019768 · form4.xml · derivative · entry 1 Theagene Jean-Manasse · CIK 0001969857 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,910 Underlying: Common Stock · 8,910 shares Expires 2033-06-30 F1 · derivative.exercise_date: The stock options, granted on June 30, 2023 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 10:30 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | GrantStock Options · Derivative | 945 | $0.00 Strike: $3.46 | $0.00 |
DisclosureSEC source: 0001127602-23-012013 · form4.xml · derivative · entry 1 Theagene Jean-Manasse · CIK 0001969857 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 945 Underlying: Common Stock · 945 shares Expires 2033-03-31 F1 · derivative.exercise_date: The stock options, granted on March 31, 2023 pursuant to MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.